ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...
Pfizer agreed to spend $11 billion to buy Array BioPharma, a company that is developing small molecule medicines primarily to treat cancer. Pfizer agreed to spend $11 billion to buy Array BioPharma, a ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...
BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) announced today that the strategic alliance between Array and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ...
Over 1.2 million people in the US are living with melanoma, according to the National Cancer Institute‘s 2015 estimates, with the number of new cases steadily increasing. NCI estimates that 91,270 ...
* Array Biopharma Inc - FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - FDA set a target action ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...
* Array to receive $12 million in up-front payment and up to $64 million in additional development and commercialization milestones * Array retains full commercialization rights for all compounds in ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results